The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 14, 2020
Filed:
Nov. 07, 2016
Applicant:
Idac Theranostics, Inc., Tokyo, JP;
Inventors:
Shin-ichi Hashimoto, Kanazawa, JP;
Shuichi Kaneko, Kanazawa, JP;
Masao Honda, Kanazawa, JP;
Takayoshi Shirasaki, Kanazawa, JP;
Taro Yamashita, Kanazawa, JP;
Assignee:
IDAC THERANOSTICS, INC., Tokyo, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/7105 (2006.01); A61K 31/713 (2006.01); C12N 15/113 (2010.01); A61K 31/7088 (2006.01); A61K 48/00 (2006.01); A61K 31/4178 (2006.01); A61K 31/4525 (2006.01); C12Q 1/6883 (2018.01); C12Q 1/70 (2006.01); A61K 45/06 (2006.01); C12Q 1/6886 (2018.01); G01N 33/569 (2006.01); A61P 31/20 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7105 (2013.01); A61K 31/4178 (2013.01); A61K 31/4525 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); A61P 31/20 (2018.01); C12N 15/113 (2013.01); C12Q 1/6883 (2013.01); C12Q 1/6886 (2013.01); C12Q 1/706 (2013.01); G01N 33/56983 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2500/02 (2013.01); G01N 2500/04 (2013.01); G01N 2500/10 (2013.01); Y02A 50/385 (2018.01); Y02A 50/387 (2018.01); Y02A 50/389 (2018.01); Y02A 50/391 (2018.01); Y02A 50/393 (2018.01); Y02A 50/463 (2018.01); Y02A 50/465 (2018.01);
Abstract
The present invention relates to an antiviral drug comprising as an active ingredient a substance capable of suppressing an expression of a target gene or an activity of a protein encoded by said target gene, wherein said target gene is one or more genes having an action of retaining virus-derived nucleic acid in a host cell and selected from the group consisting of DOCK11 gene, LIPG gene, DENND2A gene, and HECW2 gene. The present invention also relates to a screening method for the antiviral drug.